share_log

Some Investors May Be Willing To Look Past Biogen's (NASDAQ:BIIB) Soft Earnings

Some Investors May Be Willing To Look Past Biogen's (NASDAQ:BIIB) Soft Earnings

一些投資者可能願意忽視百健(納斯達克股票代碼:BIIB)的軟收益
Simply Wall St ·  05/01 07:03

Biogen Inc.'s (NASDAQ:BIIB) recent soft profit numbers didn't appear to worry shareholders, as the stock price showed strength. However, we think the company is showing some signs that things are more promising than they seem.

Biogen Inc. 's(納斯達克股票代碼:BIIB)最近的疲軟利潤數字似乎並沒有讓股東感到擔憂,因爲股價表現出強勁。但是,我們認爲該公司顯示出一些跡象,表明情況比看起來更有希望。

earnings-and-revenue-history
NasdaqGS:BIIB Earnings and Revenue History May 1st 2024
NASDAQGS: BIIB 收益和收入歷史記錄 2024 年 5 月 1 日

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

For anyone who wants to understand Biogen's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by US$573m due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Biogen to produce a higher profit next year, all else being equal.

對於任何想了解Biogen超出法定數字的利潤的人來說,值得注意的是,在過去的十二個月中,由於不尋常的項目,法定利潤減少了5.73億美元。看到不尋常的項目使公司利潤付出代價從來都不是一件好事,但從好的方面來看,情況可能遲早會好轉。我們調查了數千家上市公司,發現不尋常的物品本質上往往是一次性的。而且,畢竟,這正是會計術語的含義。假設這些不尋常的支出不會再次出現,因此,在其他條件相同的情況下,我們預計Biogen明年將實現更高的利潤。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On Biogen's Profit Performance

我們對百健盈利表現的看法

Because unusual items detracted from Biogen's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Biogen's earnings potential is at least as good as it seems, and maybe even better! Unfortunately, though, its earnings per share actually fell back over the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. At Simply Wall St, we found 2 warning signs for Biogen and we think they deserve your attention.

由於不尋常的項目削弱了Biogen去年的收益,因此你可以爭辯說,我們可以預期本季度的業績會有所改善。因此,我們認爲Biogen的盈利潛力至少和看起來一樣好,甚至可能更好!但不幸的是,其每股收益實際上在去年有所回落。歸根結底,如果你想正確地了解公司,必須考慮的不僅僅是上述因素。考慮到這一點,除非我們對風險有透徹的了解,否則我們不會考慮投資股票。在Simply Wall St,我們發現了兩個Biogen的警告標誌,我們認爲它們值得你關注。

Today we've zoomed in on a single data point to better understand the nature of Biogen's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我們放大了單個數據點,以更好地了解Biogen利潤的性質。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論